ACLA, anti-cardiolipin antibody; AFP, alpha feto protein; BCS, Budd-Chiari syndrome; CDUS, color doppler ultrasonography; CT, computed tomography; CTP, Child Turcotte Pugh; EHPVO, extra hepatic portal venous obstruction; EST, endoscopic sclerotherapy; HCC, hepatocellular carcinoma; HVPG, hepatic venous pressure gradient; IGF-1, insulin like growth factor-1; IGFBP-3, insulin like growth factor binding protein-3; INR, international normalized ratio; JAK-2, Janus kinase 2; LA, lupus anticoagulant; LMWH, low molecular weight heparin; MELD, model for end stage liver disease; MPD, myeloproliferative disorder; MRI, magnetic resonance imaging; MTHFR, methylenetetrahydrofolate reductase; MVT, mesenteric vein thrombosis; OCPs, oral contraceptive pills; PAI-1 4G-4G, plasminogen activator inhibitor type 1- 4G/4G genotype; PNH, paroxysmal nocturnal hemoglobinuria; PV, portal vein; PVT; PVT, portal vein thrombosis; PWUS, Pulsed Wave ultrasonography; RFA, radio frequency ablation; SMA, superior mesenteric artery; SMV, superior mesenteric vein; TAFI, thrombin activatable fibrinolysis inhibitor; TARE, Trans arterial radioembolization; TB, tuberculosis; TIPS, transjugular intrahepatic portosystemic shunt; UFH, unfractionated heparin; acute and chronic; anticoagulation; imaging; prothrombotic; rtPA, recombinant tissue plasminogen activator